NasdaqGS - Nasdaq Real Time Price USD

Cumberland Pharmaceuticals Inc. (CPIX)

4.9700

+0.1250

+(2.58%)

At close: April 25 at 4:00:00 PM EDT

4.9700

+0.02

+(0.40%)

After hours: April 25 at 4:05:08 PM EDT

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in th

PR Newswire last month

CPIX
+2.58%
Cumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023)

Cumberland Pharmaceuticals ( NASDAQ:CPIX ) Full Year 2024 Results Key Financial Results Revenue: US$37.9m (down 4.3...

Simply Wall St. last month

CPIX
+2.58%
Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call

Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

CPIX
+2.58%
Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

CPIX reports an 11.6% increase in Q4 revenue and FDA approval for Vibativ in China, while navigating net losses and high operating expenses.

GuruFocus.com last month

CPIX
+2.58%
Cumberland: Q4 Earnings Snapshot

The Nashville, Tennessee-based company said it had a loss of 14 cents per share. Losses, adjusted for non-recurring costs and stock option expense, were 2 cents per share. The pharmaceutical company posted revenue of $10.4 million in the period.

Associated Press Finance last month

CPIX
+2.58%
Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. Net revenues for the full year 2024 were $38 million.

PR Newswire last month

CPIX
+2.58%
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025.

PR Newswire last month

CPIX
+2.58%
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China. The announcement follows an agreement between the companies providing SciClone the exclusive rights to register, promote and distribute the product to patients in that country. The NMPA is the

PR Newswire 2 months ago

CPIX
+2.58%
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

Clinical Trials Arena 2 months ago

CPIX
+2.58%
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on T

Benzinga 2 months ago

CPIX
+2.58%
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it's the first successful Phase 2 study specifically targeting the cardiac c

PR Newswire 2 months ago

CPIX
+2.58%
3 US Penny Stocks With Market Caps Over $30M

As the U.S. markets experience fluctuations with major indices like the Dow Jones and Nasdaq reacting to earnings reports, investors are keenly observing economic indicators that could influence future interest rate decisions. In this context, penny stocks—typically smaller or newer companies—remain an intriguing investment area despite their somewhat outdated label. These stocks can offer surprising value and potential for growth, especially when backed by strong financials, making them a...

Simply Wall St. 3 months ago

CPIX
+2.58%
FRGE
3 Promising Penny Stocks With Market Caps Under $2B In US

As U.S. markets experience a slight pullback with the S&P 500 and Nasdaq Composite shedding some recent gains, investors are closely watching for opportunities amid fluctuating indices. For those looking to invest in smaller or newer companies, penny stocks—despite the name's vintage feel—can still offer surprising value. These stocks, often overlooked, can present compelling opportunities when backed by strong financials and growth potential, making them attractive options for investors...

Simply Wall St. 4 months ago

CPIX
+2.58%
INTR

CMRX
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change

FDA approval of Acetadote's simplified dosing propels Cumberland Pharmaceuticals' stock to a 90% single-day surge

GuruFocus.com 4 months ago

CPIX
+2.58%
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

On Monday, the FDA approved Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX) supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen. Acetaminophen, a common over-the-counter pain reliever and fever reducer, is the leading cause of acute liver failure in the United States. Eac

Benzinga 4 months ago

CPIX
+2.58%
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

Health care stocks were steady premarket Tuesday, with The Health Care Select Sector SPDR Fund (XLV)

PREMIUM
MT Newswires 4 months ago

LLY

CPIX
+2.58%
FDA APPROVES ACETADOTE® sNDA

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. Acetadote is an intravenous (IV) formulation of N-acetylcysteine (NAC) indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen1.

PR Newswire 4 months ago

CPIX
+2.58%
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)

Cumberland Pharmaceuticals ( NASDAQ:CPIX ) Third Quarter 2024 Results Key Financial Results Revenue: US$9.09m (down...

Simply Wall St. 5 months ago

CPIX
+2.58%
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...

Despite weather-related disruptions and product challenges, CPIX reports strong revenue growth and strategic international expansions.

GuruFocus.com 5 months ago

CPIX
+2.58%
Cumberland: Q3 Earnings Snapshot

CPIX) on Thursday reported a loss of $1.5 million in its third quarter. The Nashville, Tennessee-based company said it had a loss of 11 cents per share. Losses, adjusted for non-recurring costs and stock option expense, were 2 cents per share.

Associated Press Finance 5 months ago

CPIX
+2.58%

Performance Overview

Return	CPIX	S&P 500 (^GSPC)
YTD	+109.70%	-6.06%
1-Year	+192.35%	+9.44%
3-Year	+94.90%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cumberland Pharmaceuticals Inc. (CPIX)

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Cumberland Pharmaceuticals Full Year 2024 Earnings: US$0.46 loss per share (vs US$0.44 loss in FY 2023)

Q4 2024 Cumberland Pharmaceuticals Inc Earnings Call

Cumberland Pharmaceuticals Inc (CPIX) Q4 2024 Earnings Call Highlights: Revenue Growth and ...

Cumberland: Q4 Earnings Snapshot

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

3 US Penny Stocks With Market Caps Over $30M

3 Promising Penny Stocks With Market Caps Under $2B In US

Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

FDA APPROVES ACETADOTE® sNDA

Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023)

Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ...

Cumberland: Q3 Earnings Snapshot

Performance Overview